欧洲泌尿外科学会生化复发风险分类作为挽救性放疗决策工具:一项多中心研究
该多中心研究纳入2379例根治性前列腺切除术后生化复发患者,评估欧洲泌尿外科学会(EAU)风险分层对挽救性放疗(SRT)选择的指导价值。高危生化复发患者早期SRT较未SRT显著改善12年总生存(81% vs 66%,p<0.001)和肿瘤特异性生存(98% vs 82%,p<0.001);低危生化复发患者早期SRT与未SRT的总生存和肿瘤特异性生存均无显著差异。作者建议高危生化复发患者推荐早期SRT,低危患者可考虑监测。
要点
- 高危生化复发患者早期SRT较未SRT的12年总生存为81% vs 66%(p<0.001),肿瘤特异性生存为98% vs 82%(p<0.001)。
- 低危生化复发患者早期SRT与未SRT的12年总生存为87% vs 78%(p=0.2),肿瘤特异性生存为100% vs 96%(p=0.2),均无显著差异。
- 作者建议高危生化复发男性推荐早期SRT,低危生化复发可考虑监测。
核心结论
- 高危生化复发组中接受早期SRT的患者较观察组录得生存改善;作者建议高危生化复发男性推荐早期SRT。
- 低危生化复发患者中,随访期间仅9例死于前列腺癌,监测可能是合适选择。
研究设计与样本
- 分析1989年至2020年间十个欧洲高容量中心2379例根治性前列腺切除术后发生生化复发的患者。
- 早期SRT定义为前列腺特异性抗原<0.5 ng/ml时给予SRT,晚期SRT定义为前列腺特异性抗原≥0.5 ng/ml时给予SRT。
- 采用多变量Cox模型检验SRT与未SRT对死亡和肿瘤特异性死亡的影响,采用Simon-Makuch法检验各风险组内生存差异。
主要发现
- 805例和1574例患者分别被分类为EAU低危和高危生化复发。
- 存活者生化复发后中位随访54个月。
- 低危生化复发:早期SRT与未SRT的12年总生存为87% vs 78%(p=0.2),肿瘤特异性生存为100% vs 96%(p=0.2)。
- 高危生化复发:早期SRT与未SRT的12年总生存为81% vs 66%(p<0.001),肿瘤特异性生存为98% vs 82%(p<0.001)。
- 多变量分析中,早期SRT降低死亡风险(HR 0.55,p<0.01)和肿瘤特异性死亡风险(HR 0.08,p<0.001);晚期SRT是肿瘤特异性死亡的预测因素(HR 0.17,p<0.01),但不是死亡的预测因素(p=0.1)。
关键数值与推荐
- EAU生化复发风险分类将患者分为低危和高危两组,本研究中共805例低危和1574例高危。
- 早期SRT定义为PSA<0.5 ng/ml时给予SRT,晚期SRT定义为PSA≥0.5 ng/ml时给予SRT。
临床怎么用
- 作者建议高危生化复发男性推荐早期SRT。
- 作者认为低危生化复发患者监测可能是合适选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Association of Urology (EAU) has proposed a risk stratification for patients harboring biochemical recurrence (BCR) after radical prostatectomy (RP). OBJECTIVE: To assess whether this risk stratification helps in choosing patients for salvage radiotherapy (SRT). DESIGN, SETTING, AND PARTICIPANTS: Analyses of 2379 patients who developed BCR after RP (1989-2020), within ten European high-volume centers, were conducted. Early and late SRT were defined as SRT delivered at prostate-specific antigen values <0.5 and ≥0.5 ng/ml, respectively. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox models tested the effect of SRT versus no SRT on death and cancer-specific death. The Simon-Makuch method tested for survival differences within each risk group. RESULTS AND LIMITATIONS: Overall, 805 and 1574 patients were classified as having EAU low- and high-risk BCR. The median follow-up was 54 mo after BCR for survivors. For low-risk BCR, 12-yr overall survival was 87% versus 78% (p = 0.2) and cancer-specific survival was 100% versus 96% (p = 0.2) for early versus no SRT. For high-risk BCR, 12-yr overall survival was 81% versus 66% (p < 0.001) and cancer-specific survival was 98% versus 82% (p < 0.001) for early versus no SRT. In multivariable analyses, early SRT decreased the risk for death (hazard ratio [HR]: 0.55, p < 0.01) and cancer-specific death (HR: 0.08, p < 0.001). Late SRT was a predictor of cancer-specific death (HR: 0.17, p < 0.01) but not death (p = 0.1). CONCLUSIONS: Improved survival was recorded within the high-risk BCR group for patients treated with early SRT compared with those under observation. Our results suggest recommending early SRT for high-risk BCR men. Conversely, surveillance might be suitable for low-risk BCR, since only nine patients with low-risk BCR died from prostate cancer during follow-up. PATIENT SUMMARY: The impact of salvage radiotherapy (SRT) on cancer-specific outcomes stratified according to the European Association of Urology biochemical recurrence (BCR) risk classification was assessed. While men with high-risk BCR should be offered SRT, surveillance might be a suitable option for those with low-risk BCR.
引用
- Preisser F, Abrams-Pompe RS, Stelwagen PJ, et al. European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study. Eur Urol. 2023. PMID: 37355358. doi:10.1016/j.eururo.2023.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。